The effect of the duration of clopidogrel use on hsCRP levels after stenting the target vessel in patients with acute coronary syndrome

Clinical and Investigative Medicine

Volumn 34, Issue 4, 2011, Pages

  Çekici, Yusuf ^a   Korkmaz, Hasan ^b   Çelik, Ahmet ^b   Bilen, Mehmet Nail ^a   Bulut, Musa ^a   Akbulut, Mehmet ^a  

^a FIRAT UNIVERSITY   (Turkey)

^b Elazig Education and Research Hospital ^*  (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; CLOPIDOGREL; DRUG DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ARTICLE; CLINICAL TRIAL; DRUG ELUTING STENT; HUMAN; METABOLISM;

ACUTE CORONARY SYNDROME; C-REACTIVE PROTEIN; DRUG-ELUTING STENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 80051824683     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Inoue T, Kato T, Uchida T, Sakuma M, Nakajima A, Shibazaki M, et al. Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. J Am Coll Cardiol 2005; 46: 239-45.
2. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:1 15-26.
3. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovas cular risk prediction. J Intern Med 2002; 252: 283-94.
4. Gottsauner-Wolf M, Zasmeta G, Hornykewycz S, Nikfardjam M, Stepan E, Wexberg P, et al. Plasma levels of C-reactive pro tein after coronary stent implantation. Eur Heart J 2000; 21: 1152-8.
5. Chew DP, Bhatt DL, Robbins MA, Penn MS, Schneider JP, Lauer MS, et al. Incremental prognostic value of elevated base line C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001; 104: 992-7.
6. Yip HK, Hang CL, Fang CY, Hsiesh YK, Yang CH, Hung HW, et al. Level of high sensivity C-reactive protein is predictive of 30-day outcomes in patients with acute myocardial infarction undergoing primary coronary intervention. Chest 2005; 127: 803-8.
7. Montone RA, Ferrante G, Bacà M, Niccoli G. Predictive value of C-reactive protein after drug-eluting stent implantation. Future Cardiol. 2010; 6: 167-79.
8. Buffon A, Liuzzo G, Biasucci LM, Pasqualetti P, Ramazzotti V, Rebuzzi AG, et al. Preprocedural serum concentrations of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999;34: 1512-1521.
9. Niccoli G, Montone RA, Ferrante G, Crea F. The evolving role of inflammatory biomarkers in risk assessment after stent im plantation. J Am Coll Cardiol. 2010; 56: 1783-93
10. Muhlestein JB. Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. Thromb Haemost. 2010; 103: 71-82.
11. Steinhubl S R, Berger PB, Mann JT, Fry ET, DeLago A, Wilmer C, et al. CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary interven tion: a randomized controlled trial. JAMA 2002; 288: 2411-20.
12. Herrmann J, Lerman A, Baumgart D, Volbracht L, Schulz R, von Birgelen C, et al. Pre-procedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 2002; 106: 2180-3.
13. Zouki C, Beauchamp M, Baron C, Filep JG. Prevention of In vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. J Clin Invest. 1997; 100: 522-9.
14. Lowe GD, Yarnell JW, Rumley A, Bainton D, Sweetnam PM. C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in pathogenesis ? Arterioscler Thromb Vasc Biol 2001; 21: 603-10.
15. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-65.
16. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating mark ers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.
17. Allantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atheroscle rosis Risk in Communities (ARIC) study. Circulation 2004; 109: 837-42.
18. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with un stable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina Refrac tory to standard treatment trial. J Am Coll Cardiol 2000; 35: 1535-42.
19. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000; 343: 1139-47.
20. Chew DP, Bhatt DL, Robbins MA, Penn MS, Schneider JP, Lauer MS, et al. Incremental prognostic value of elevated base line C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001; 104: 992-7.
21. Walter DH, Fichtlscherer S, Britten MB, Rosin P, Auch-Schwelk W, Schachinger V, et al. Statin therapy, inflammation and recur rent coronary events in patients following coronary stent im plantation. J Am Coll Cardiol 2001; 38: 2006-12.
22. Park DW, Yun SC, Lee JY, Kim WJ, Kang SJ, Lee SW, et al. C-reactive protein and the risk of stent thrombosis and cardiovas cular events after drug-eluting stent implantation. Circulation 2009; 120: 1987-95.
23. Libby P. Current concept of the pathogenesis of the acute coro nary syndromes. Circulation 2001; 104: 365-72.
24. Aukrust P, Waehre T, Damas JK, Gullestad L, Solum NO. Inflammatory role of platelets in acute coronary syndromes. Heart 2001; 56: 605-606.
25. Gurbel PA, Bliden KP, Hiatt BL, O'Connar CM. Clopidogrel for coronary stenting: response variability drug resistance, and effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-13.
26. Zihui X, Pierre T. Clopidogrel inhibits platelet-leukocyte inter actions and thrombin receptor agonist peptide induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 2004; 43: 1982-8.
27. Klinkhardt U, Graff J, Harder S. Clopidogrel but not abciximab reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model. Clin Pharmacol Ther 2002; 71: 176-85.
28. Feldman M, Jilial I, Devaraj S, Cryer B. Effects of lowe dose aspi rin and tromboxone B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 2001; 37: 2036-41.
29. Chew DP, Bhatt DL, Robbins MA, et al. Effects of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 2001; 88: 672-4.
30. Bhatt DL, Zidar F, Chew DP. Effect of clopidogrel pretreatment marker expression in patient undergoing percutaneous coronary intervention. Am J Cardiol 2004; 93: 679-84
31. Azar RR, Kassab R, Zoghbi A, Aboujaoudé S, El-Osta H, Ghorra P et al. Effects of clopidogrel on soluble CD40 ligand and on high-sensivity C-reactive protein in patients with stable coronary artery disease. Am Heart J 2006; 151: 521
32. WoodWard M, Lowe GD, Francis LM, Rumley A, Cobbe SM; CADET study Investigators. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: The CA DET trial. J Thromb Haemost 2004; 11: 1934-40.
33. Van der Wall AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atheroscle rotic plaques is characterized by an inflamatory process irrespec tive of the dominant plaque morphology. Circulation 1994; 89: 36-44.
34. Biasucci LM, Liuzzo G, Grillo RL, Caliguri G, Rebuzzi AG, Buffon A, et al. Elevated concentrations of C-recavtive protein at discharge in patiens with unstable angina predict recurrent instability. Circulation 1999; 99: 855-60.
35. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
36. Kang WC, Ahn TH, Moon CI, Han SH, Shin EK. Impact of arterial remodeling on high sensitive C-reactive protein after a DES implantation. Int J Cardiol. 2010; 145: 325-6.